Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Depletion of CD8 lymphocytes in CD8 Ab-treated macaques resulted in a significant decrease in BCG vaccine-induced immunity against tuberculosis after <i>M. tuberculosis</i> infecti... by Crystal Y. Chen (122165)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Number of alveoli based on data from Tschanz et al. [6] together with our linearly scaled data (our data multiplied by 5.04). by David Haberthür (8407422)

Linear mixed model results: Effect of bar height and approach stride number on sagittal joint kinematics at take-off to a jump in agility dogs. by Leena Inkilä (20614460)

Decreased TRPV4 activity enhances the uptake of acLDL, but not oxLDL. by Erika J. Gruber (11846156)

Dopamine decreases the refractive power in the lens periphery. by J. Marcus Schartau (365288)

“…<p>(A) The mean ΔBCD curves describe the difference between the treated and untreated lenses from all animals (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0010402#s4" target="_blank">Methods and Materials</a>). …”

Relationship between mean horizontal speed and mean decreases in oxygen saturation during the run. by Eva Bernardi (3897652)

Reuse of paths within years (i.e., their thickness, a proxy for the directedness of movement) decreased in response to wildfire despite an increase in overall number of paths. by Aishwarya Subramanian (14930268)